Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial

Journal of Infectious Diseases

Volumn 180, Issue 4, 1999, Pages 1342-1346

  Hoen, Bruno ^a   Dumon, Béatrice ^b   Harzic, Martine ^c   Venet, Alain ^d   Dubeaux, Béatrice ^c   Lascoux, Caroline ^e   Bourezane, Yazid ^a   Ragnaud, Jean Marie ^b   Bicart See, Alain ^f   Raffi, François ^g   Beauvais, Laurianne ^h   Fleury, Hervé ^b   Séréni, Daniel ^e  

^a HÔPITAL SAINT JACQUES   (France)

^b HÔPITAL PELLEGRIN   (France)

^c CENTRE HOSPITALIER DE VERSAILLES   (France)

^d INSTITUT COCHIN   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f CHU PURPAN   (France)

^g HÔTEL DIEU   (France)

^h GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ANTI-HIV AGENTS; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LYMPHOCYTE COUNT; MALE; RITONAVIR; RNA, VIRAL; VIRAL LOAD; ZIDOVUDINE;

EID: 0033393313     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315002     Document Type: Article

References (15)

1. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257.
2. Kinloch-de-Loës S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. New Engl J Med 1995; 333:408-13.
3. Niu MT, Bethel J, Holodniy M, Standiford HC, Schnittman SM. Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection a randomized, double-blind, placebo-controlled trial. J Infect Dis 1998; 178:80-91.
4. Lafeuillade A, Poggi C, Profizi N, Tamalet C, Costes O. Human deficiency virus type 1 kinetics in lymph nodes compared with plasma. J Infect Dis 1996; 174:404-7.
5. Tamalet C, Lafeuillade A, Fantini J, Nouara Y. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy. AIDS 1997; 11:895-901.
6. Delwart EL, Shpaer EG, Louwagie J, et al. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 genes. Science 1993; 262:1257-61.
7. Perrin L, Markowitz M, Calandra G, Chung M, and the MRL acute HIV infection study group. An open treatment study of acute HIV infection with zidovudine, lamivudine and indinavir sulfate. [abstract] In: Program and abstracts: 4th Conference on Retroviruses and Opportunistic Infection (Washington, DC), Washington, DC: ISDA, 1997.
8. Hecht F, Smith D, Cooper D, Anderson R, Peterson A, Kahn JO. Treatment of primary HIV infection with nelfinavir, zidovudine, and lamuvidine. [abstract 12197] In: Program and abstrats: 12th World AIDS Conference (Geneva, Switzerland). Washington, DC: ISDA, 1998.
9. Perrin L, Yerly S, Marchal F, et al. Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy. J Infect Dis 1998; 177:1497-1501.
10. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-91.
11. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 346:1605-13.
12. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection an viral replication and antiviral immune responses. J Infect Dis 1999; 179:527-37.
13. Wong JK, Hezareh M, Günthard HF, et al. Receiver of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-5.
14. Wong JK, Günthard HF, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997; 94:12574-9.
15. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33-9.